23 citations
,
December 2013 in “Molecular cancer therapeutics” This study found that AR-positive breast cancer cell lines are more sensitive to the dual PI3K/mTOR inhibitor NVP-BEZ235 compared to AR-negative cells.
1 citations
,
March 2019 in “Actas Dermo-Sifiliográficas” This review discusses the adverse effects on hair associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for comprehensive documentation of these effects.
177 citations
,
March 2018 in “International Journal of Molecular Sciences” This review discusses the role of mTOR kinase in pulmonary fibrosis and explores how mTOR inhibitors may help slow the progression of this condition, but it reports no new results.
9 citations
,
June 2023 in “Cells” This review summarizes recent findings on how the dysregulated PI3K/Akt/mTOR pathway contributes to immune-mediated inflammatory skin disorders and discusses the potential of natural products, synthetic compounds, and biologic agents in their treatment. However, it emphasizes the need for further research to develop effective therapies.
8 citations
,
January 1977 in “Acta Haematologica” This study found that the PVP protocol, combining Peptichemio, vincristine, and 6-methylprednisolone, resulted in remission for diffuse non-Hodgkin's lymphomas with moderate side effects.
February 2006 in “Inpharma Weekly”
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” This study used machine learning to identify molecular predictors of drug response in alopecia areata, suggesting a tool for predicting treatment efficacy based on gene signatures.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” This study suggests that HDAC inhibitors, such as Vorinostat and Entinostat, could be effective in promoting hair regrowth in a mouse model of alopecia areata.
222 citations
,
October 2014 in “Annual Review of Pharmacology and Toxicology” This review discusses the roles of Eph receptors and ephrins in various diseases, highlighting their potential as therapeutic targets, but it presents no new research findings.
144 citations
,
August 2019 in “Cells” This review discusses the WNT signaling pathway's involvement in human diseases and highlights recent advances in WNT-related treatments, but it presents no new research findings.
119 citations
,
November 2014 in “Trends in Cell Biology” This review discusses the mechanisms and pathways of FGFR signalling and its roles in development, disorders, and therapeutic targeting, but reports no new clinical results.
55 citations
,
September 2017 in “Expert Opinion on Drug Discovery” This review examines the main absorption sites and influencing factors for orally administered drugs, highlighting variables such as solubility and gastrointestinal conditions that affect drug absorption in the small intestine and the development of effective drug delivery systems.
27 citations
,
March 2018 in “Biomaterials” This study found that a cocktail of three proteins from embryonic skin can enable adult fibroblasts to regenerate hair follicles by altering gene expression and activating regenerative signaling pathways.
18 citations
,
June 2019 in “Twin research and human genetics” This article describes the 25Up study on psychological and behavioral risk factors for mental illness in Australian twins and their siblings and reports prevalence data for various mental disorders.
2 citations
,
January 2024 in “Pakistan Veterinary Journal” This review highlights the potential of hydrogels in veterinary medicine, emphasizing their advantages over traditional wound dressings and their promising applications in drug delivery and tissue engineering, despite currently limited use in this field.
1 citations
,
January 2026 in “Frontiers in Cell and Developmental Biology” This study reviews the transformative role of artificial intelligence in biomaterial design, highlighting its ability to reduce costs through virtual screening, enhance material performance, and predict biological interactions to advance personalized and precision medicine.
1 citations
,
March 2025 in “Frontiers in Physiology” This study identified key genes linked to immune cells and potential therapeutic compounds for alopecia areata by evaluating upregulated genes from patient datasets, highlighting T and NK cell involvement in hair follicle attack and suggesting drug candidates through molecular docking and dynamics simulations.
1 citations
,
January 2024 in “NPJ breast cancer” This study, using modified Delphi panels, provided consensus recommendations for managing alpelisib-induced hyperglycemia and rash, advising prophylactic metformin starting for certain risk groups and the use of nonsedating H1 antihistamines and topical steroids for initial rash management.
December 2025 in “Journal of Ovarian Research” This study found that multiple vitamins, including B6, increased the number of growing follicles in newborn mouse ovaries in vitro. VB6 promoted primordial follicle activation via the PI3K/Akt signaling pathway in both cultured mouse and human ovarian tissues.
January 2025 in “Institutional Repositories DataBase (IRDB)” This study observed that topical application of maslinic acid stimulated hair growth in mice comparably to minoxidil, possibly through the Wnt/β-catenin pathway and involving ciliary gene activity, highlighting increased levels of trichogenic gene expression and protein levels.
November 2024 in “Open Repository of the University of Porto (University of Porto)” This report details a six-month internship experience, split between hospital and community pharmacy settings, which enhanced practical skills and theoretical knowledge in pharmaceutical care and highlighted the pharmacist's role in ensuring safe medication use.
July 2022 in “Berkala Ilmu Kesehatan Kulit dan Kelamin/Berkala ilmu kesehatan kulit dan kelamin (Periodical of dermatology and venerology)” This study reviewed medical records of tinea capitis patients at a clinic in Surabaya, finding that the condition predominantly affected young males and was often associated with contact with cats.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.
This study found that a mitoxantrone, vincristine, and prednisolone regimen effectively treated recurrent breast cancer with a 70% response rate, though it was associated with significant myelosuppression.
1 citations
,
August 1983 in “PubMed” This study reported that VCP combination chemotherapy achieved a complete response in 53% of advanced non-Hodgkin's lymphoma patients, although more intensive treatment may be needed for improved outcomes.
January 1994 in “Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics” In this study, both VEPA and ML-Y1 treatment regimens for older patients with non-Hodgkin's lymphoma showed similar response and survival rates, but neither was sufficient, indicating the need for a more effective approach.
1 citations
,
April 2023 in “Heliyon” In this study, a 68-year-old man with muscle-invasive bladder cancer and renal insufficiency achieved a partial radiological response to neoadjuvant therapy with gemcitabine and Disitamab Vedotin, without significant adverse events, highlighting a potential alternative for cisplatin-ineligible patients.
17 citations
,
January 2025 in “Journal of Nanobiotechnology” This review discusses the potential of bacterial extracellular vesicles in regenerative medicine, highlighting their advantages in addressing current EV challenges, and provides strategies for optimizing their preparation; it reports no new clinical results.
176 citations
,
June 2016 in “PLoS ONE” In these initial clinical studies, NAP monotherapy showed significant reductions in HBsAg levels among patients with chronic HBV, suggesting potential as part of future combination therapies.
79 citations
,
January 1982 in “The American Journal of Medicine” This study reports that VP-16-213 (etoposide) shows significant therapeutic activity in several cancers including small cell bronchogenic carcinoma and certain leukemias, with hematologic toxicity being the primary side effect.